EUCTR2007-000593-24-SE进行中（未招募）不适用
An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria: Group A Only
- •1a. Naïve to either etanercept or adalimumab, or who may have received prior anti-TNF therapy and displayed an intolerance but is now considered to be appropriate candidate for treatment with either etanercept or adalimumab.
- •Inclusion Criteria: Group B Only
- •1b. History (as documented in the patient’s medical records) of initial clinical response to either etanercept or adalimumab and a subsequent loss of clinical response. Initial clinical response is defined as attainment of Good or Moderate response by EULAR criteria during the first 3 months of anti-TNF therapy; the consistency of the response must be documented on at least
- •two consecutive occasions separated by at least 4 weeks. Loss of response to therapy is defined as DAS 28 score = 4.5 and increase or worsening in DAS 28 by = 1.2 from lowest DAS achieved on anti-TNF therapy, in at least two consecutive
- •evaluations separated by at least 4 weeks. A documented loss of response is required prior to study screening. Confirmation of loss of response will occur at the Screening Visit.
- •Inclusion Criteria: Groups A and B
- •Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •Diagnosis of RA at least 3 months prior to start of anti-TNF therapy, according to the revised 1987 ACR criteria.
- •Age 18–80 years, inclusive.
- •If on corticosteroids, dose must be = 10 mg prednisone (or equivalent) for at least 2 weeks prior to baseline assessment.
- •Must have inadequate response to MTX at a dose of 10-25 mg/week (po or parenteral) for = 12 weeks, of which the 4 weeks immediately prior to the baseline visit have been at a stable dose.
- •Swollen joint count (SJC) = 4 (28 joint count), and tender joint count (TJC) = 4 (28 joint count) at baseline.
- •At screening, either; CRP = 0.6 mg/dL (6 mg/L) with high sensitivity assay OR ESR = 28 mm/h.
- •At least one active joint that is appropriate for biopsy.
- •Positive for rheumatoid factor (RF) or anti-CCP.
- •If female, and of child bearing potential, must agree to use a reliable form of contraception (eg.hormonal contrceptive, patch, intra-uterine device, physical barrier) during the study and for 5 months following the last dose of prescribed anti-TNF therapy.
- •If male, must agree to use(with his partner) a reliable form of contraception (hormonal contrceptive, patch, intra-uterine device, physical barrier method), during the study and for 5 months following the last dose of prescribed anti-TNF therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria: Groups A and B
- •Patients with any of the following will be excluded from the study:
- •Any contraindication for entanercept or adalimumab treatment according to the approved product label.
- •Pregnant or Breast feeding
- •History of or current inflammatory joint disease or autoimmune disease other than RA.
- •Treatment with sulfasalazine, hydroxychloroquine, chloroquine,D-penicillamine, auranofin, azathioprine, cyclosporine, or tacrolimus = 4 weeks prior to baseline, or abatacept or leflunomide = 8 weeks before baseline.
- •Treatment with any investigational agent = 4 weeks prior to baseline or < 5 half-lives of the investigational drug or where persisting PD effect (eg, cell depletion) of investigational therapy on target cells or pathways to RA (whichever is longer). Previous treatment with alkylating agents or cell-depleting therapies, including investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti-CD11a, Blys, BAFF, anti-CD22 and anti-CD20).
- •Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline.
- •Intra-articular or parenteral corticosteroids = 2 weeks prior to
- •Intra-articular treatment of the joint selected for biopsy within 3 months of baseline visit.
- •History of heart failure.
- •Evidence of significant uncontrolled concomitant diseases such
- •as neurological, cardiovascular, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the investigator, would preclude patient participation.
研究者
相似试验
进行中（未招募）
1 期
An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.Rheumatoid Arthritis.MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritisEUCTR2007-000593-24-GBF. Hoffmann-La Roche Ltd52
进行中（未招募）
1 期
An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (SOM230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients with Nelson's Syndrome. - Pasireotide Therapy in Patients with Nelson's Syndrome Version 1.1elson's SyndromeEUCTR2009-014457-33-GBSheffield Teaching Hospitals NHS Foundation Trust8
进行中（未招募）
不适用
Open label, uncontrolled pilot study on the effect of mucosal healing with 3 g mesalazine granules in NSAID induced small bowel enteropathy, evaluated by video capsule endoscopy after 4 weeks of treatment.An investigator initiated phase II pilot study.EUCTR2007-001317-42-HUProf. Dr. Istvan Racz10
进行中（未招募）
不适用
An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/AEUCTR2007-004063-21-NLBiovitrum AB18
进行中（未招募）
不适用
A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of SchizophreniaSchizophreniaEUCTR2007-003342-15-HUEli Lilly and Company Limited580